← Back to home

METASTATIC RADIOACTIVE IODINE REFRACTORY THYROID CANCER PATIENTS WITH RAS OR BRAF MUTATION

Clinical trials for METASTATIC RADIOACTIVE IODINE REFRACTORY THYROID CANCER PATIENTS WITH RAS OR BRAF MUTATION explained in plain language.

Never miss a new study

Get alerted when new METASTATIC RADIOACTIVE IODINE REFRACTORY THYROID CANCER PATIENTS WITH RAS OR BRAF MUTATION trials appear

Sign up with your email to follow new studies for METASTATIC RADIOACTIVE IODINE REFRACTORY THYROID CANCER PATIENTS WITH RAS OR BRAF MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Targeted drug duo teams up with radiation to fight stubborn thyroid cancer

Disease control Completed

This study tested whether adding two targeted drugs (trametinib and dabrafenib) could help radioactive iodine work again for people with advanced thyroid cancer that had specific genetic mutations (RAS or BRAFV600E). It involved 40 adults whose cancer had spread and was no longer…

Matched conditions: METASTATIC RADIOACTIVE IODINE REFRACTORY THYROID CANCER PATIENTS WITH RAS OR BRAF MUTATION

Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control

Last updated Mar 27, 2026 12:38 UTC

METASTATIC RADIOACTIVE IODINE REFRACTORY THYROID CANCER PATIENTS WITH RAS OR BRAF MUTATION

Get alerted when new METASTATIC RADIOACTIVE IODINE REFRACTORY THYROID CANCER PATIENTS WITH RAS OR BRAF MUTATION trials appear

Targeted drug duo teams up with radiation to fight stubborn thyroid cancer